Pandora Wealth Inc. Sells 5,400 Shares of TG Therapeutics, Inc. $TGTX

Pandora Wealth Inc. cut its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 6.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 78,300 shares of the biopharmaceutical company’s stock after selling 5,400 shares during the period. TG Therapeutics accounts for 1.7% of Pandora Wealth Inc.’s holdings, making the stock its 14th biggest holding. Pandora Wealth Inc.’s holdings in TG Therapeutics were worth $2,818,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its stake in shares of TG Therapeutics by 54.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company’s stock valued at $898,000 after purchasing an additional 8,338 shares in the last quarter. New York State Teachers Retirement System boosted its stake in shares of TG Therapeutics by 175.0% during the first quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company’s stock valued at $4,746,000 after purchasing an additional 76,600 shares in the last quarter. Crossmark Global Holdings Inc. bought a new position in shares of TG Therapeutics during the first quarter valued at approximately $226,000. GAMMA Investing LLC boosted its stake in shares of TG Therapeutics by 77.7% during the first quarter. GAMMA Investing LLC now owns 4,543 shares of the biopharmaceutical company’s stock valued at $179,000 after purchasing an additional 1,986 shares in the last quarter. Finally, Strs Ohio bought a new position in shares of TG Therapeutics during the first quarter valued at approximately $785,000. 58.58% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on TGTX shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 target price for the company in a research note on Thursday, July 10th. B. Riley raised their target price on shares of TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Finally, HC Wainwright assumed coverage on shares of TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 target price for the company. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $49.00.

Insider Activity

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the firm’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the transaction, the director owned 94,061 shares of the company’s stock, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 10.64% of the company’s stock.

TG Therapeutics Price Performance

Shares of TGTX opened at $33.76 on Monday. The company has a market cap of $5.36 billion, a price-to-earnings ratio of 91.24 and a beta of 1.97. TG Therapeutics, Inc. has a twelve month low of $21.65 and a twelve month high of $46.48. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. The company has a 50 day moving average of $31.51 and a two-hundred day moving average of $35.17.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). The company had revenue of $141.15 million during the quarter, compared to analysts’ expectations of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The company’s quarterly revenue was up 92.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.04 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.